[14] Several factors contributed to the efficacy of the treatment in patients with NSCLS with acquired resistance to EGFR TKI (local or slow/minimal progression); such factors include special clinical course of acquired resistance disease, continuation of TKI therapy for sensitive tumor cells, and potential benefits of local treatment. This evidence concerns the gene EGFR and neoplasm.